

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Compleat if Known	
				Application Number	Unassigned
				Filing Date	
				First Named Inventor	Rahman et al.
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Sheet	1	of	1	Attorney Docket Number	224491

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
JR	AA	5,834,012		Perez-Soler et al.	Nov. 10, 1998	
JR	AB	6,214,388	B1	Benz et al.	April 10, 2001	

Class/Seq.
424/450
424/812

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
JR	AC	WO	95/08986		Smithkline Beecham Corporation	April 6, 1995		

Class/Seq.

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
JR	AD	Y. Sadzuka, "Effective Prodrug Liposome and Conversion to Active Metabolite," <i>Current Drug Metabolism</i> , 1(1), 31-48 (2000).		
JR	AE	Sadzuka, "Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11," <i>Cancer Letters</i> , 127, 99-106 (1998).		

Examiner Signature	Jeffrey E. Russel	Date Considered	February 24, 2005
--------------------	-------------------	-----------------	-------------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).